Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $0.8t | $990.00 | -1.5% | 2.0M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.5t | $228.92 | +1.0% | 10.1M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $349.7b | $211.00 | +0.3% | 5.1M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $289.5b | $183.50 | +1.1% | 1.2M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $271.8b | $112.56 | +1.1% | 8.0M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $183.1b | $324.22 | -0.6% | 2.0M |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $160.4b | $129.66 | +0.1% | 5.2M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $119.0b | $57.40 | +0.7% | 11.7M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $76.7b | $629.64 | -9.8% | 3.0M |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $30.8b | $144.25 | -1.0% | 2.3M |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $28.6b | $192.57 | +3.3% | 2.1M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $22.0b | $52.06 | -1.5% | 3.4M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $19.5b | $95.15 | -0.2% | 1.0M |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $18.7b | $48.16 | -1.8% | 5.0M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $12.8b | $229.59 | +0.4% | 685.9K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $11.4b | $49.85 | -0.6% | 2.6M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $10.9b | $95.64 | +0.8% | 1.2M |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $8.0b | $99.93 | -2.3% | 440.7K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $7.6b | $67.42 | +0.5% | 1.8M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $7.2b | $8.02 | +0.6% | 13.1M |
 ACLX | Arcellx, Inc. Common Stock | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $6.7b | $115.06 | -0.0% | 16.1M |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.2b | $31.34 | -4.1% | 1.7M |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.8b | $132.34 | -3.9% | 721.4K |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $5.8b | $62.90 | -6.0% | 1.4M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $5.4b | $93.17 | -0.8% | 1.4M |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $5.2b | $15.11 | +3.8% | 5.4M |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $5.0b | $55.14 | -2.2% | 816.5K |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $3.6b | $20.64 | +0.4% | 3.3M |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $3.6b | $86.08 | +4.2% | 600.5K |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.1b | $23.40 | -1.6% | 1.1M |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.1b | $10.28 | +0.5% | 3.0M |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $2.8b | $68.48 | -3.0% | 1.2M |
 IMNM | Immunome, Inc. | Radiopharmaceuticals & ADCsTargeted Therapy & Precision Oncology | $2.7b | $19.88 | -4.8% | 1.3M |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $2.7b | $41.48 | +7.8% | 1.5M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.6b | $39.63 | -4.1% | 510.8K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.6b | $28.32 | +0.4% | 907.1K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.3b | $12.10 | -0.9% | 2.3M |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $2.2b | $12.71 | -1.0% | 1.6M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $2.1b | $60.76 | +1.9% | 421.2K |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.1b | $35.67 | -3.7% | 757.3K |
 ZYME | Zymeworks Inc. | Targeted Therapy & Precision Oncology | $2.1b | $24.43 | +2.1% | 750.2K |
 INBX | Inhibrx Biosciences, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $1.9b | $105.89 | -2.5% | 393.8K |
 SNDX | Syndax Pharmaceuticals, Inc. | Immunotherapy & Immuno-Oncology | $1.9b | $19.41 | -4.0% | 1.4M |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $1.8b | $15.52 | -2.1% | 2.2M |
 VIR | Vir Biotechnology, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.7b | $8.78 | -0.1% | 1.5M |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $1.6b | $4.28 | -0.9% | 4.6M |
 NTLA | Intellia Therapeutics, Inc | Cell & Gene Therapy for Cancer | $1.6b | $12.68 | -7.2% | 9.6M |
 IMTX | Immatics N.V. Ordinary Shares | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $1.6b | $10.60 | -2.5% | 680.3K |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.5b | $18.01 | -0.8% | 642.1K |